US Senate clears PEPFAR bill with HIV treatment thresholds
This article was originally published in Scrip
Executive Summary
The US House is expected this week to approve a Senate bill renewing and expanding the President's Emergency Plan for AIDS Relief (PEPFAR) programme. The measure would require more than half of all HIV/AIDS funding be spent on treatment and open an avenue for the PEPFAR programme to purchase antiretrovirals approved by regulators other than the FDA.
You may also be interested in...
Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos
Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.
Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos
Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.